New Strategies for the Drug Development of Anti-cerebral Ischemia
—Advances in the Etiology and Drug Development of Acute Cerebral Ischemia

doi:10.3969/j.issn.2095-1396.2018.01.001

Abstract

Abstract: Acute cerebral ischemia （stroke） is a major disease which threat to people’s health because of its high incidence，high mortality and high morbidity. Of particular concern is that the clinical application of a serious lack of prevention and treatment of drugs，and a large number of research and development of drugs has not been successful. This paper analyzes the current status of prevention and treatment of acute cerebral ischemia drugs and the reasons for its lack of success. It is proposed that a new strategy is necessary for new drug development and research. Based on the recognization of the analysis of the disease pathology and drug research，we suggested the disease pathogenesis and features based strategy and pathological process based drug development strategies.

Key words: acute cerebral ischemia, prevention and treatment of drugs for stroke, drugresearch and development strategy

CLC Number:

R964

DU Guan-hua，ZHANG Wen，DU Li-da，MA Yin-zhong，LI Li，WANG Yue-hua. New Strategies for the Drug Development of Anti-cerebral Ischemia
—Advances in the Etiology and Drug Development of Acute Cerebral Ischemia[J]. Acta Neuropharmacologica, 2018, 8(1): 1-8.

References

[1] 陈伟伟, 高润霖, 刘力生, 等.《中国心血管病报告2016》概要[J]. 中国循环杂志, 2017, 32(6): 617-622.

[2] Richard H Swartz, Mark Bayley, Krista L Lanctôt, et al. Post-stroke depression, obstructive sleep apnea, and cognitive impairment: rationale for, and barriers to, routine screening[J]. Int J Stroke, 2016, 11(5): 509-518.

[3] Guzik Amy, Bushnell Cheryl. Stroke epidemiology and risk factor management [J]. Continuum (Minneap Minn), 2017, 23(1, Cerebrovascular Disease): 15-39.

[4] Mark J Alberts. Stroke treatment with intravenous tissue-type plasminogen activator[M]. Am Heart Assoc, 2017, 135(2):140-142.

[5] Adams H P, Adams R J, Brott T, et al. Guidelines for the early management of patients with ischemic stroke[J]. Stroke, 2003, 34(4): 1056-1083.

[6] 瓮长水, 孙启良.《日本脑卒中治疗指南》(2004’) 康复部分简介[J]. 中国康复医学杂志, 2005, 20(7): 534-538.

[7] 中华医学会神经病学分会. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015, 48(4): 246-257.

[8] Xu Sui-yi, Pan Su-yue. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy[J]. Med Sci Monit Basic Res, 2013, 19(19): 37-45.

[9] Marc Fisher. New approaches to neuroprotective drug development[J]. Stroke, 2011, 42(1 suppl 1): S24-S27.

[10] Angel Chamorro, Ulrich Dirnagl, Xabier Urra, et al. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation[J]. The Lancet Neurology, 2016, 15(8): 869-881.

[11] Stephen Grupke, Jason Hall, Michael Dobbs, et al. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview[J]. Clin Neurol Neurosurg, 2015, 129: 1-9.

[12] Kaste M. Is there a future for neuroprotective agents in acute ischaemic stroke?[J]. Eur J Neurol, 2012, 19(6): 797-798.

[13] Jens Minnerup, Heike Wersching, Matthias Schilling, et al. Analysis of early phase and subsequent phase III stroke studies of neuroprotectants: outcomes and predictors for success[J]. Exp Transl Stroke Med, 2014, 6(1): 2.

[14] Zhang Qing-hua, Wang Chao, Zheng Mao-yong, et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis[J]. Cerebrovasc Dis, 2015, 39(1): 13-22.

[15] Pierre Amarenco, Julien Labreuche. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention[J]. Lancet Neurol, 2009, 8(5): 453-463.

[16] Muzamil Ahmad, Nawab John Dar, Zubair Shanib Bhat Z, et al. Inflammation in ischemic stroke: mechanisms, consequences and possible drug targets[J]. CNS Neurol Disord Drug Targets, 2014, 13(8): 1378-1396.

[17] Tomasz Dziedzic. Systemic inflammation as a therapeutic target in acute ischemic stroke[J]. Expert Rev Neurother, 2015, 15(5): 523-531.

[18] Zhang Rong-rong, Xu Meng-xue, Wang Yu, et al. Nrf2-a promising therapeutic target for defensing against oxidative stress in stroke[J]. Mol Neurobiol, 2017, 54(8): 6006-6017.

[19] Dang Bao-qi, Duan Xiao-chun, Wang Zhong, et al. A therapeutic target of cerebral hemorrhagic stroke: matrix metalloproteinase-9[J]. Curr Drug Targets, 2017, 18(12): 1358-1366.

[20] Rafael Andres Posada-Duque, George E Barreto, Gloria Patricia Cardona-Gomez. Protection after stroke: cellular effectors of neurovascular unit integrity[J]. Front Cell Neurosci, 2014, 8(231): 231.

[21] Gorelick P, Grotta J, Greenwood D, et al. Recommendations for clinical trial evaluation of acute stroke therapies-Stroke Therapy Academic Industry Roundtable II (STAIR-II)[J]. Stroke, 2001, 32(7): 1598-1606.

[22] Mrac Fisher. Recommendations for advancing development of acute stroke therapies[J]. Stroke, 2003, 34(6): 1539-1546.

[23] Marc Fisher, Daniel F Hanley, George Howard, et al. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes[J]. Stroke, 2007, 38(2): 245-248.

[24]Marc Fisher. Enhancing the development and approval of acute stroke therapies[J]. Stroke, 2005, 36(8): 1808-1813.

[25] Marc Fisher, Giora Zeev Feuerstein, David W Howells, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations[J]. Stroke, 2009, 40(6): 2244-2250.

[26] Jeffrey L Saver, Gregory W Albers, Billy Dunn, et al. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials[J]. Stroke, 2009, 40(7): 2594-2600.

[27] Saver J L, Jovin T G, Smith W S, et al. Stroke treatment academic industry roundtable [J]. Stroke, 2013, 44(12): 3596-3601.

[28] Jovin T G, Albers G W, Liebeskind D S, et al. Stroke Treatment Academic Industry Roundtable[J]. Stroke, 2016, 47(10): 2656-2665.

[29]Karin E Sandoval, Ken A Witt. Blood-brain barrier tight junction permeability and ischemic strok[J]. Neurobiol Dis, 2008, 32(2): 200-219.

[30] Liu Jia-ling, Wang Yong-ting, Yosuke Akamatsu, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials[J]. Prog Neurobiol, 2014, 115: 138-156.

[31] Peter M Rothwell, Ale Algra, Chen Zheng-ming, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials[J]. Lancet, 2016, 388(10042): 365-375.

[32] Mora S, Ames J M, Manson J E. Low-dose aspirin in the primary prevention of cardiovascular disease: shared decision making in clinical practice[J]. JAMA, 2016, 316(7): 709-710.

[33] Praful M Dalal, Madhumita Bhattacharjee. Stroke epidemic in India: hypertension-stroke control programme is urgently needed[J]. J Assoc Physicians India, 2007, 55:689-691.

[34] Funaki S, Tokutomi F, Wada-Takahashi S, et al. Porphyromonas gingivalis infection modifies oral microcirculation and aortic vascular function in the stroke-prone spontaneously hypertensive rat (SHRSP)[J]. Microb Pathog, 2016, 92: 36-42.

[35] Joon-Tae Kim, Gregg C Fonarow, Eric Smith, et al. Treatment with tPA in the "golden hour" and the shape of the 4.5 hour time-benefit curve in the national US Get With the Guidelines-Stroke population[J]. Circulation, 2016,. 135(2): 128-139.

[36] Wang Meng-die, Yin Xiao-xv, Yang Ting-ting, et al. Chinese neurologists’ perspective on intravenous thrombolysis for acute ischemic stroke[J]. Brain Behav, 2017, 8(1):e00882.

[37] Wang Yi-long, Liao Xiao-ling, Zhao Xing-quan, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China[J]. Stroke, 2011, 42(6): 1658-1664.

[38] Yang Yi, Gary A Rosenberg. Blood–brain barrier breakdown in acute and chronic cerebrovascular disease[J]. Stroke, 2011, 42(11): 3323-3328.

[39] Raymond Shim, Connie H Y Wong. Ischemia, immunosuppression and infection-tackling the predicaments of post-stroke complications[J]. Int J Mol Sci, 2016, 17(1): 551-556.

[40] Rebecca A Harrison, Thalia Shoshana Field. Post stroke pain: identification, assessment, and therapy[J]. Cerebrovasc Dis, 2015, 39(3-4): 190-201.

[41] 马寅仲, 李莉, 孔令雷, 等. 匹诺塞林对大鼠脑梗死后rtPA诱导的出血性转化的预防作用及机制[J]. 中国药理学与毒理学杂志, 2016, 30(10): 1017

[42] Gao Mei, Zhu Shen-yin, Tan Chu-bing, et al. Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats[J]. J Asian Nat Prod Res, 2010, 12(5): 407-418.

[43] Meng Fan-rui, Liu Rui, Gao Mei, et al. Pinocembrin attenuates blood-brain barrier injury induced by global cerebral ischemia-reperfusion in rats[J]. Brain Res, 2011, 1391: 93-101.

[44] Shi L L, Chen B N, Gao M, et al. The characteristics of therapeutic effect of pinocembrin in transient global brain ischemia/reperfusion rats[J]. Life Sci, 2011, 88(11-12): 521-528.

[45] Wang S B, Pang X B, Gao M, et al. Pinocembrin protects rats against cerebral ischemic damage through soluble epoxide hydrolase and epoxyeicosatrienoic acids[J]. Chin J Nat Med, 2013, 11(3): 207-213.

[46] Wu Cai-xia, Liu Rui, Gao Mei, et al. Pinocembrin protects brain against ischemia/reperfusion injury by attenuating endoplasmic reticulum stress induced apoptosis[J]. Neurosci Lett, 2013, 546: 57-62.

[47] Zhao Gang, Zhang Wen, Li Li, et al. Pinocembrin protects the brain against ischemia-reperfusion injury and reverses the autophagy dysfunction in the penumbra area[J]. Molecules, 2014, 19(10): 15786-15798.

[48] Gregory J Del Zoppo, Jeffrey L Saver, Edward C Jauch, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator[J]. Stroke, 2009, 40(8): 2945-2948.

[49] Yoshihiro Murata, Anna Rosell, Robert H Scannevin, et al. Extension of the thrombolytic time window with minocycline in experimental stroke[J]. Stroke, 2008, 39(12): 3372-3377.

[50] Chamila Geeganage, Philip MW Bath. Vasoactive drugs for acute stroke[J]. Cochrane Database Syst Rev, 2010, 7: CD002839.

[51] M Ihsan Kaadan, Mary Jo Larson. Management of post-stroke depression in the Middle East and North Africa: Too little is known[J]. J Neurol Sci, 2017, 378: 220-224.